Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

ATTAIN-2

Eli Lilly · Phase 3 · Completed · Enrollment 1613

NCT05872620

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

24.449.860.2
≥5%
723.935.5
≥10%
1.97.317.7
≥15%
≥20%
Show as table
Arm≥5%≥10%≥15%≥20%
Placebo24.4%7%1.9%n/r
6 mg Orforglipron QD49.8%23.9%7.3%n/r
12 mg Orforglipron QD60.2%35.5%17.7%n/r
36 mg Orforglipron QDn/rn/rn/rn/r

Not shown

  • 36 mg Orforglipron QD: endpoint not reported